Login to Your Account

FDA Wants Breast Cancer Stricken from Avastin's Label

By Donna Young

Friday, December 17, 2010
WASHINGTON – The FDA Thursday said it wants the HER2-negative metastatic breast cancer indication stricken from the labeling of Genentech Inc.'s Avastin (bevacizumab), which gained accelerated approval in February 2008 as a first-line treatment in combination with paclitaxel for the disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription